AltPep, a spun out from the Daggett Research Group lab at the University of Washington, is a biomedical company focused on diagnosing and treating Central Nervous System amyloid disorders, starting with Alzheimer's Disease.
AltPep’s technology is based on decades of research and discoveries from the lab, culminating in technology that targets a fundamental toxic protein structure formed during amyloidogenesis.
AltPep was founded in 2019 by Valerie Daggett. The company is headquartered in Seattle, Washington.
AltPep's unique and proprietary platform specifically targets only the toxic α -sheets that lead to disease. The AltPep ™ Platform is based on a collection of de novo designed synthetic peptides. The growing library is an arsenal that specifically targets the root causes of disease at the molecular level.
AltPep holds a worldwide, exclusive license from the University of Washington to a broad intellectual property portfolio covering the platform technology and its application to an extensive array of diagnostics, therapeutics, and vaccines for amyloid-related diseases.
AltPep is backed by Matrix Capital Management, Alexandria Venture Investments, and others. The company raised $44.4M in a new financing on Jul 27, 2022. This brings AltPep's total funding to $67.6M to date.